Clinical Trial Update: Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial in de novo kidney transplant patients comparing a calcineurin inhibitor–free or low-dose regimen to a standard CNI-based regimen has completed, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2017-01-18